Declan Jones,

Vice President, Scientific Innovation, Neuroscience

Declan is Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation. In this role, Declan uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer’s Disease and Mood Disorders.

Declan previously worked for GSK’s Centre of Excellence for External Drug Discovery (CEEDD) as Head of Research.  He was responsible for creating scientific strategies, identifying external opportunities, and managing programs from preclinical to Phase II programs across all therapeutic areas.

Prior to GSK’s CEEDD, he spent 14 years in GSK’s neuroscience R&D, finishing as Head of In Vivo Neurobiology and Strategy Leader for schizophrenia and bipolar disorders within the Psychiatry Centre of Excellence for Drug Discovery. Declan was the recipient of an R&D Pipeline award for his leadership of a schizophrenia program with a successful Phase II outcome.

Declan received his PhD from the University of Bradford and did post-doctoral work at Emory University and University of Hertfordshire before joining the pharmaceutical industry.  He is currently an Executive Team member for the Dementias Platform UK (DPUK) and the Wellcome Trust Neuroinflammation Consortium, and is a SAB member for the UK Dept of Health (PM’s Dementia Challenge) and the South London and Maudsely NHS Foundation Trust Biomedical Research Centre at the Institute of Psychiatry, Psychology, and Neuroscience (King’s College London), and works closely with the Dementia Discovery Fund.


Declan Jones
Declan Jones